Renal pelvis carcinoma
MONDO:0005519A carcinoma arising in the renal pelvis. The majority of renal pelvis carcinomas are transitional cell and less frequently squamous cell carcinomas.
Also known as: cancer of renal pelvis, malignant neoplasm of renal pelvis, malignant renal pelvis neoplasm, malignant tumour of renal pelvis, renal pelvis cancer, carcinoma of kidney pelvis, carcinoma of renal pelvis, carcinoma of the kidney pelvis
2786 clinical trials for this condition and its sub-types, 15 tagged with Renal pelvis carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Renal pelvis carcinoma
-
Renal pelvis urothelial carcinoma 16 trials
3 sub-types
-
Carcinoma in situ of renal pelvis 0 trials
-
Renal pelvis adenocarcinoma 0 trials
-
Renal pelvis squamous cell carcinoma 0 trials
-
New cocktail of drugs takes on Hard-to-Treat bladder cancer
Disease control Recruiting nowThis early-phase trial tests a combination of three drugs—enfortumab vedotin, pembrolizumab, and quemliclustat—in people with advanced bladder or urinary tract cancer that has spread or cannot be removed by surgery. The goal is to see if the combination is safe and effective. The…
Phase 1/2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New Antibody-Drug conjugate targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug cocktail aims to stop kidney cancer recurrence in High-Risk patients
Disease control Recruiting nowThis study tests whether adding tivozanib to the standard immunotherapy pembrolizumab works better than pembrolizumab alone to keep kidney cancer from returning after surgery. About 1040 adults with high-risk clear cell renal cell carcinoma will take part. The goal is to see if t…
Phase 3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug combo aims to save kidneys in pelvic cancer patients
Disease control Recruiting nowThis phase II trial tests whether a combination of tislelizumab (an immunotherapy) and nab-paclitaxel (a chemotherapy drug) can treat renal pelvic cancer while allowing patients to keep their kidney. About 35 adults with early-stage cancer will receive the drugs, and if the tumor…
Phase 2 • Sponsor: Tianjin Medical University Second Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Blood test aims to catch Cancer's return earlier
Diagnosis Recruiting nowThe ORACLE study watches people who have finished treatment for early-stage solid tumors, such as lung, breast, colon, and pancreatic cancers. Researchers want to see if a blood test called Guardant Reveal can find tiny traces of tumor DNA that might signal the cancer is coming b…
Sponsor: Guardant Health, Inc. • Aim: Diagnosis
Last updated Sep 16, 2026 00:00 UTC